Róbert Wessman-led Aztiq and Innobic join forces in $475m acquisition of Lotus Pharmaceutical and Adalvo to create a global pharmaceutical powerhouse - Seite 3

shareholder value."

NOTES TO EDITORS:

About Aztiq

- Aztiq is a long-term healthcare investor focused on pharmaceuticals, led by
Alvogen founder and chairman Robert Wessman. Going forward, Aztiq will be
acting as a specialized pharmaceutical fund advisor and manager investing in
various pharmaceutical assets.
- Aztiq's shareholder base consists of individual investors as well as major
international investment funds among whose largest assets are pharmaceuticals
companies Alvogen, Alvotech, Lotus, Almatica, Almaject and Adalvo.
- Established in 2009, Aztiq was founded on the principle that everyone should
have the right to medicine, regardless of their financial means.

Relevant history

- Alvogen acquired a majority stake in Lotus in 2014 and since then Lotus has
evolved into a next-generation pharmaceuticals company focused on global
oncology, with direct market access in more than 10 countries in Asia and a
portfolio with global into more than 130 markets.
- Since 2018, Alvogen has evolved Adalvo from an in-house B2B platform into a
separate business unit focusing on global markets. Adalvo has rapidly achieved
remarkable growth, with over 500 transactions and a world-class portfolio of
60 differentiated medicines. It is currently one of the fastest growing B2B
pharmaceutical company globally, serving partners and patients in over 100
markets around the world.

Photo: https://mma.prnewswire.com/media/1696901/Virtual_Signing.jpg

Logo: https://mma.prnewswire.com/media/1696676/AZTIQ_Logo.jpg

Contact:

Aztiq Head of PR and Strategy
Lára Ómarsdóttir
E-mail: [e-mail]
[phone]

Additional content: http://presseportal.de/pm/160268/5083331
OTS: Aztiq Fjárfestingar ehf